Inflammatory Bowel Diseases Clinical Trial
— GLI-IBDOfficial title:
The Effects of Combined Lifestyle Intervention (CLI) in Patients With Inflammatory Bowel Disease (IBD)
A single-center observational study to investigate the effects of combined lifestyle intervention (CLI, in Dutch: gecombineerde leefstijlinterventie, GLI) in patients with Inflammatory Bowel Disease.
Status | Not yet recruiting |
Enrollment | 40 |
Est. completion date | February 1, 2025 |
Est. primary completion date | February 1, 2025 |
Accepts healthy volunteers | |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Age = 18 years old; - Diagnosis of IBD (Ulcerative Colitis, Crohn's Disease or IBD-Unclassified) confirmed by clinical, endoscopic, and histological evidence prior to screening as per standard criteria; - BMI = 30 mg/kg2 or a BMI between 25 and 30 mg/kg2 and an increased risk of diabetes or cardiovascular disease; - Patients that are or have been referred to the CLI; - Oral informed consent must be obtained and documented in EPIC. Exclusion Criteria: - Serious underlying disease other than IBD that in the opinion of the investigator may interfere with the subject's ability to participate fully in the study or would compromise subject safety (such as major neurological disorders, certain orthopedic impairments or any unstable, uncontrolled or severe systemic medical disorder); - If female, the subject is pregnant or lactating; - Illiteracy (disability to read and understand Dutch). |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Radboud University Medical Center |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Decrease in bodyweight | Measured in kilograms | 2 years | |
Primary | Decrease in BMI | Measures in mg/kg2 | 2 years | |
Primary | Decrease in waist circumference | Measured in centimeters | 2 years | |
Primary | Decrease in fat percentage | Measured in percentages | 2 years | |
Primary | Quality of life | EQ-5D-5L score | 2 years | |
Secondary | Adherence | Adherence to the CLI (i.e. amount of patients to stop the CLI prematurely) | 2 years | |
Secondary | Willingness | Willingness to partake in the CLI (and to be referred to the CLI) | 2 years | |
Secondary | IBD related adverse events | Incidence of IBD related adverse events during the study period | 2 yera |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04046913 -
The ADDapt Diet in Reducing Crohn's Disease Inflammation
|
N/A | |
Active, not recruiting |
NCT04989907 -
A Study in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) Receiving Vedolizumab in Real-World Practice in Switzerland
|
||
Recruiting |
NCT05316584 -
A Novel Remote Patient and Medication Monitoring Solution to Improve Adherence and PerSiStence With IBD Therapy
|
N/A | |
Active, not recruiting |
NCT04990258 -
A 24-month Real Life PErsistence Efficacy and Safety Study in IBD Patients in REMission Switched From Intravenous Infliximab to Subcutaneous Infliximab CT-P13 Remsima®SC
|
||
Completed |
NCT06216223 -
Laser Versus Surgery in Anal Diseases in Inflammatory Bowel Patients
|
N/A | |
Enrolling by invitation |
NCT06015789 -
Self-care in Patients Affected by Inflammatory Bowel Disease and Caregivers' Contribution to Self-care
|
||
Recruiting |
NCT06065995 -
StoMakker Mobile Application
|
N/A | |
Recruiting |
NCT03282786 -
Comparison of Carbon Dioxide (CO2) to Air Insufflation in Colonoscopy in Patients With Inflammatory Bowel Disease
|
N/A | |
Recruiting |
NCT06002074 -
SMART Program Impact on Quality of Life in Inflammatory Bowel Diseases
|
N/A | |
Recruiting |
NCT04960826 -
Study of an Environmental Risk Factor in Crohn's Disease
|
||
Recruiting |
NCT05413941 -
Internet-based Cognitive Behavioral Therapy in Inflammatory Bowel Disease
|
N/A | |
Completed |
NCT03668249 -
A Study to Characterize Multidimensional Model to Predict the Course of Crohn's Disease (CD)
|
||
Completed |
NCT00721812 -
A First Time In Human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GSK1399686
|
Phase 1 | |
Recruiting |
NCT05809999 -
IBD Neoplasia Surveillance RCT
|
N/A | |
Recruiting |
NCT04138225 -
The Ecological Role of Yeasts in the Human Gut
|
||
Recruiting |
NCT04991324 -
Cholecalciferol Comedication in IBD - the 5C-study
|
Phase 3 | |
Completed |
NCT03173144 -
Chronic Inflammatory Disease, Lifestyle and Treatment Response
|
||
Not yet recruiting |
NCT05043818 -
A Clinical Study on the Screening of Intestinal Biomarkers in IBD Patients With Depression
|
||
Recruiting |
NCT03042091 -
Neomycin and Metronidazole Hydrochloride With or Without Polyethylene Glycol in Reducing Infection in Patients Undergoing Elective Colorectal Surgery
|
Early Phase 1 | |
Not yet recruiting |
NCT02858557 -
The Effect of Diet on Microbial Profile and Disease Outcomes in Patients With Inflammatory Bowel Diseases
|
N/A |